Reuters logo
BRIEF-Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit
November 28, 2017 / 4:48 AM / 17 days ago

BRIEF-Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit

Nov 28 (Reuters) - Glenmark Pharmaceuticals Ltd:

* GLENMARK PHARMACEUTICALS SAYS ‍BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017

* GLENMARK PHARMACEUTICALS LTD SAYS ‍U.S. FDA ISSUED 7 OBSERVATIONS VIA FORM 483​​ Source text: bit.ly/2i9U3Ul Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below